RHHBY - Roche upgraded on Alzheimer's hopes QIAGEN price target trimmed - today's analyst action

Mario13/E+ via Getty Images Roche upgraded Jefferies on Alzheimer’s prospects Expecting Roche (RHHBY) to confirm its intention to pursue an expedited U.S. filing for marketing approval of Alzheimer’s therapy gantenerumab, Jefferies has upgraded the stock to buy from hold. The price target upped to CHF400 from CHF330 implies a premium of ~12.8%. The analyst Peter Welford now predicts the late 2022 launch of gantenerumab with $6B peak sales by 2032. Early this month, Jefferies revealed internal management discussions at Roche indicating an “expedited” U.S. filing of gantenerumab. QIAGEN price target lowered at Citi after updated guidance Despite a rise in 2021 estimates for the company’s base business, the impact on COVID-19 testing expectations has prompted Citi to slash the price target of QIAGEN (QGEN) to $58.00 from $65.00 per share to imply a premium of ~23.0%. Citing a conference call hosted by the management after its preliminary revenue estimates for Q2

For further details see:

Roche upgraded on Alzheimer’s hopes, QIAGEN price target trimmed - today's analyst action